Latest Licensing News

Triangle Energy’s June quarter report reveals a strategic pivot as key JV partners exit, the Cliff Head assets transition to carbon capture, and promising exploration prospects remain in focus.

White Energy Company Limited reported promising exploration results across multiple Australian projects targeting critical minerals, alongside progress in commercialising its innovative coal briquetting technology in South Africa.

Patrys Limited has completed a modest capital raise and restructured its leadership as it advances its deoxymab antibody program, with a larger entitlement offer announced to fund clinical development and business growth.

Genesis Resources has completed its acquisition of full ownership of the Plavica project in North Macedonia and is advancing environmental studies while preparing for drilling campaigns in Australia’s Northern Territory.

Biotron Limited has successfully raised $1.27 million through an entitlement issue to fund its antiviral drug development, including a promising Hepatitis B compound that cleared its initial animal safety study.

ENRG Elements Limited has appointed new management and implemented significant cost reductions while renewing key uranium exploration permits in Niger. The company is also exiting lithium projects in Canada to focus on core assets and new opportunities.

Holista Colltech reported steady customer receipts and a 38% surge in dietary supplement sales for 2QFY25, while progressing its high-value nano-collagen business and refreshing its leadership team.

Accent Resources has initiated a Pre-Feasibility Study for its Magnetite Range Iron Ore Project, while maintaining steady gold resources at Norseman and reporting a strong cash position of $13 million.

Diatreme Resources has formalised a negotiation framework with the Gulaal People, setting the stage for collaborative development of its Northern Silica Project while prioritising cultural heritage and community benefits.

First Lithium Limited is on the cusp of securing critical mining license renewals in Mali and anticipates releasing its maiden Mineral Resource Estimate this quarter, while managing funding and exploration cost pressures.

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.

Avecho Biotechnology reports strong progress in its Phase III clinical trial for a CBD-based insomnia treatment, with recruitment accelerating across multiple Australian sites and interim results expected early next year.